Prelude Therapeutics (PRLD) announced the publication of two abstracts with preclinical data on the Company’s JAK2V617F mutant selective inhibitors and CALR-targeted degrader antibody conjugates, DACs, discovery program, both accepted for oral presentation at the American Society of Hematology, ASH, 67th Annual Meeting taking place in Orlando, FL December 6-9, 2025. The abstracts can be found on the ASH 2025 website ASH Annual Meeting & Exposition.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRLD:
- Prelude Therapeutics Advances with PRT7732 in Targeted Cancer Therapy
- Prelude Therapeutics Appoints Katina Dorton to Board
- Prelude Therapeutics appoints Katina Dorton to board of directors
- Prelude Therapeutics: Promising SMARCA2-Targeted Degraders and Positive Outlook Support Buy Rating
- Prelude Therapeutics Regains Nasdaq Compliance